See more : Big Sky Growth Partners, Inc. (BSKYU) Income Statement Analysis – Financial Results
Complete financial analysis of Clinuvel Pharmaceuticals Limited (CLVLY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Clinuvel Pharmaceuticals Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Achison Inc. (ACHN) Income Statement Analysis – Financial Results
- China Renaissance Holdings Limited (1911.HK) Income Statement Analysis – Financial Results
- Berli Jucker Public Company Limited (BJC-R.BK) Income Statement Analysis – Financial Results
- Aadi Industries Limited (AADIIND.BO) Income Statement Analysis – Financial Results
- Aspira Women’s Health Inc. (AWH) Income Statement Analysis – Financial Results
Clinuvel Pharmaceuticals Limited (CLVLY)
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88.18M | 78.32M | 65.72M | 47.98M | 32.57M | 31.05M | 25.49M | 16.77M | 6.82M | 3.32M | 2.66M | 1.55M | 722.80K | 1.04M | 0.00 | 0.00 | 0.00 | 283.31K | 754.85K | 124.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 10.08M | 27.73M | 19.10M | 12.77M | 14.13M | 445.36K | 949.77K | 615.08K | 1.94M | 5.91M | 372.14K | 166.45K | 0.00 | 0.00 | 0.00 | 916.54K | 945.44K | 957.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 78.10M | 50.59M | 46.62M | 35.20M | 18.43M | 30.60M | 24.54M | 16.15M | 4.88M | -2.59M | 2.29M | 1.39M | 722.80K | 1.04M | 0.00 | -916.54K | -945.44K | -673.86K | 754.85K | 124.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 88.57% | 64.59% | 70.93% | 73.38% | 56.60% | 98.57% | 96.27% | 96.33% | 71.61% | -78.08% | 86.03% | 89.28% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | -237.85% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.35M | 1.27M | 1.23M | 547.55K | 341.30K | 91.45K | 53.64K | 129.81K | 133.46K | 231.96K | 2.94M | 4.02M | 4.89M | 7.19M | 7.42M | 9.99M | 6.11M | 4.47M | 4.00M | 5.22M | 5.54M | 949.44K | 373.00K | 462.73K | 0.00 |
| General & Administrative | 1.74M | 1.32M | 1.15M | 1.10M | 1.15M | 4.78M | 6.69M | 4.88M | 5.59M | 10.51M | 4.54M | 4.52M | 4.66M | 4.92M | 5.83M | 6.21M | 8.18M | 4.53M | 4.64M | 3.16M | 1.77M | 1.35M | 1.01M | 427.94K | 0.00 |
| Selling & Marketing | 27.21M | 7.09M | 11.15M | 6.87M | 1.89M | 1.50M | 1.05M | 811.43K | 777.73K | 801.56K | 516.14K | 602.80K | 806.43K | 626.39K | 704.14K | 845.90K | 1.41M | 1.66M | 1.08M | 883.84K | 640.55K | 118.28K | 108.00K | 0.00 | 0.00 |
| SG&A | 28.95M | 8.41M | 12.30M | 7.96M | 7.89M | 6.29M | 6.34M | 5.30M | 4.70M | 5.63M | 4.86M | 5.12M | 5.46M | 5.54M | 6.54M | 7.06M | 9.59M | 6.18M | 5.72M | 4.05M | 2.41M | 1.47M | 1.12M | 427.94K | 0.00 |
| Other Expenses | 0.00 | 763.08K | 821.15K | -1.24M | 781.32K | 880.48K | 485.84K | 96.11K | 796.53K | 470.27K | 440.41K | 1.01M | -94.84K | 45.80K | 2.67M | -679.54K | -945.44K | -925.45K | 3.80M | 6.34M | 926.48K | 2.49M | 748.00K | -775.00K | 0.00 |
| Operating Expenses | 31.30M | 9.68M | 13.53M | 8.51M | 8.23M | 13.03M | 11.84M | 9.30M | 8.25M | 8.17M | 8.14M | 9.83M | 11.03M | 13.77M | 16.38M | 18.19M | 18.85M | 11.56M | 11.66M | 12.45M | 8.74M | 4.91M | 4.15M | 36.00K | 0.00 |
| Cost & Expenses | 39.03M | 37.41M | 32.64M | 21.28M | 22.37M | 13.48M | 12.79M | 9.92M | 10.18M | 14.08M | 8.52M | 9.83M | 11.03M | 13.77M | 16.38M | 19.11M | 19.79M | 12.51M | 11.66M | 12.45M | 8.74M | 4.91M | 4.15M | 36.00K | 0.00 |
| Interest Income | 7.32M | 3.91M | 444.07K | 342.20K | 562.93K | 543.54K | 242.19K | 264.39K | 208.37K | 348.41K | 326.47K | 410.46K | 571.24K | 1.18M | 1.47M | 2.67M | 4.30M | 2.24M | 446.96K | 476.94K | 355.24K | 136.40K | 258.00K | 408.70K | 0.00 |
| Interest Expense | 4.45M | 3.19M | 2.27M | 1.62M | 25.89K | 21.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.14M | 789.41K | 757.83K | 861.43K | 446.13K | 214.16K | 44.54K | 53.14K | 25.53K | 26.54K | 37.47K | 57.97K | 62.50K | 91.90K | 716.15K | 830.56K | 841.76K | 905.19K | 914.67K | 823.85K | 790.29K | 794.26K | 786.00K | 36.00K | 0.00 |
| EBITDA | 56.28M | 41.70M | 33.84M | 28.19M | 10.64M | 16.78M | 12.26M | 6.85M | -4.16M | -11.23M | -6.29M | -8.22M | -10.24M | -12.64M | -15.66M | -17.36M | -18.01M | -10.37M | -9.99M | -11.51M | -7.94M | -4.11M | -3.36M | -1.18M | 0.00 |
| EBITDA Ratio | 63.82% | 53.24% | 51.49% | 57.44% | 32.68% | 54.05% | 48.10% | 40.87% | -51.67% | -325.54% | -217.50% | -529.47% | -1,417.21% | -1,214.10% | 0.00% | 0.00% | 0.00% | -3,617.22% | -1,160.33% | -9,232.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 49.15M | 40.91M | 33.08M | 26.70M | 10.20M | 16.69M | 12.21M | 6.80M | -3.55M | -10.83M | -5.83M | -8.28M | -10.31M | -12.73M | -16.38M | -18.19M | -18.85M | -11.27M | -10.90M | -12.33M | -8.74M | -4.91M | -4.18M | -1.97M | 0.00 |
| Operating Income Ratio | 55.74% | 52.23% | 50.34% | 55.65% | 31.31% | 53.76% | 47.93% | 40.55% | -52.04% | -326.34% | -218.91% | -533.21% | -1,425.86% | -1,222.93% | 0.00% | 0.00% | 0.00% | -3,979.38% | -1,444.27% | -9,893.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.53M | 686.82K | -1.77M | -983.49K | 439.79K | -6.11M | -5.20M | -3.61M | -3.21M | -1.96M | 303.86K | 1.48M | 538.90K | 1.32M | 4.86M | 2.82M | 4.19M | 2.10M | 133.01K | 1.30M | 1.15M | 930.66K | 1.04M | 408.28K | 0.00 |
| Income Before Tax | 50.68M | 45.58M | 34.32M | 25.71M | 11.54M | 18.11M | 12.94M | 7.11M | -3.15M | -10.41M | -5.53M | -6.80M | -9.77M | -11.41M | -11.52M | -15.37M | -14.66M | -9.18M | -10.77M | -11.03M | -7.59M | -3.98M | -3.14M | -1.56M | -374.15K |
| Income Before Tax Ratio | 57.47% | 58.19% | 52.22% | 53.60% | 35.44% | 58.35% | 50.78% | 42.43% | -46.24% | -313.91% | -207.50% | -438.04% | -1,351.30% | -1,095.95% | 0.00% | 0.00% | 0.00% | -3,238.92% | -1,426.65% | -8,849.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 15.04M | 14.97M | 13.44M | 984.40K | -3.51M | 19.33K | 281.78K | -45.31K | -609.06K | -16.34K | 0.00 | -468.44K | -633.74K | -1.28M | -2.19M | -3.50M | -5.14M | -3.02M | -133.01K | -11.03M | -7.59M | -3.98M | -3.14M | -1.56M | -374.15K |
| Net Income | 35.64M | 30.60M | 20.88M | 24.73M | 16.65M | 18.13M | 13.22M | 7.18M | -3.12M | -10.40M | -5.53M | -6.80M | -9.77M | -11.41M | -11.52M | -15.37M | -14.66M | -9.18M | -10.77M | -11.03M | -7.59M | -3.98M | -3.14M | -1.56M | 0.00 |
| Net Income Ratio | 40.41% | 39.08% | 31.77% | 51.54% | 51.12% | 58.41% | 51.89% | 42.83% | -45.76% | -313.41% | -207.50% | -438.04% | -1,351.30% | -1,095.95% | 0.00% | 0.00% | 0.00% | -3,238.92% | -1,426.65% | -8,849.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.70 | 0.62 | 0.42 | 0.50 | 0.31 | 0.38 | 0.28 | 0.15 | -0.07 | -0.24 | -0.14 | -0.19 | -0.32 | -0.38 | -0.38 | -0.51 | -0.48 | -0.37 | -0.64 | -0.84 | -0.66 | -0.44 | -0.35 | -0.22 | 0.00 |
| EPS Diluted | 0.70 | 0.59 | 0.40 | 0.48 | 0.30 | 0.37 | 0.27 | 0.14 | -0.07 | -0.24 | -0.14 | -0.19 | -0.32 | -0.38 | -0.38 | -0.51 | -0.48 | -0.37 | -0.64 | -0.84 | -0.66 | -0.44 | -0.35 | -0.22 | 0.00 |
| Weighted Avg Shares Out | 51.05M | 49.41M | 49.41M | 49.41M | 49.26M | 48.19M | 47.74M | 47.67M | 45.29M | 43.37M | 38.70M | 35.30M | 30.76M | 30.36M | 30.32M | 30.31M | 30.24M | 24.82M | 16.77M | 13.14M | 11.44M | 9.09M | 9.03M | 7.17M | 9.03M |
| Weighted Avg Shares Out (Dil) | 51.03M | 51.82M | 51.78M | 51.13M | 50.46M | 49.60M | 49.59M | 49.63M | 45.29M | 43.37M | 38.70M | 35.30M | 30.76M | 30.36M | 30.32M | 30.31M | 30.24M | 24.82M | 16.77M | 13.14M | 11.44M | 9.09M | 9.03M | 7.17M | 9.03M |
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE® (afamelanotide) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP)....
Afamelanotide in fair-skinned Parkinson's patients
MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson's Disease (PD or Parkinson's) in fair-skinned patients. The program objectives are to determine whether afamelanotide – through...
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company's unique history and future growth...
Malibu shines a light on CLINUVEL's pioneering work in photomedicine
MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California's most prolific investors and philanthropists at the Malibu home of Lady Gaga and Michael Polansky.
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2022 Results - Earnings Call Transcript
Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2022 Results - Earnings Call Transcript
CLINUVEL expands DNA Repair Program
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V)
Clinuvel publishes its long-awaited Strategic update
Clinuvel Pharmaceutical has introduced its first commercial product “Scenesse” in Europe and the US in 2014 and 2019 for the rare disease “EPP”. Since then, it has stayed very secretive about its future growth pathways, much to the dismay of...
Source: https://incomestatements.info
Category: Stock Reports